1xbet 등록 Pharmaceutical Co., Ltd.
Pharmaceuticals
August 1, 2012
Vasopressin V2-Receptor Antagonist, Samsca®Tablets Were Filed Additional Indication 1xbet 등록 the Treatment 1xbet 등록 Fluid Retention Associated with Cirrhosis 1xbet 등록 the Liver
- Application for additional indication as the world's first aquaretic treatment for water retention due to cirrhosis 1xbet 등록 the liver.
- About one-third 1xbet 등록 the approximately 270,000 liver cirrhosis patients in Japan suffer from lifestyle interference due to fluid retention (swelling 1xbet 등록 the hands and feet; abdominal bloating).
- An innovative, first-in-class treatment born from 27 years 1xbet 등록 research and development now being brought to 13 countries around the world.
Tokyo, Japan, July 31, 2012 -- 1xbet 등록 Pharmaceutical Co., Ltd. today announced that it applied in July to Japan's Ministry of Health, Labour and Welfare for an additional indication for Samsca®Tablets (tolvaptan), a V2-vasopressin receptor antagonist, as the world's first aquaretic treatment for fluid retention associated with cirrhosis 1xbet 등록 the liver.
Latest Pharmaceutical Business related News Releases